11 June 2018 - - New York, New York-based biopharmaceutical and healthcare products specialist Pfizer Inc. (NYSE: PFE) has plans to invest USD 600m in biotechnology and other emerging growth companies through Pfizer Ventures, the company's venture investment vehicle, the company said.
Initial areas of interest for Pfizer Ventures include neuro-degeneration, neuro-inflammation and neuro-metabolic disorders, and other areas where rapidly advancing science could lead to breakthroughs for patients.
Pfizer Ventures will seek to invest approximately 25% of its available capital (USD150 m) in promising early-stage neuroscience companies.
By leveraging an equity investment model, Pfizer can support a broad array of early neuroscience research and product development opportunities, which are critical in this nascent area of science.
Pfizer Ventures actively manages an existing investment portfolio of more than 40 companies. Combined with approximately USD 500m invested to date, the additional funding brings Pfizer Ventures' total assets under management to more than USD 1bn.
Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. Its global portfolio includes medicines and vaccines as well as consumer health care products.
The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world.